Claire Yang, Natalie Rosenwasser, Xing Wang, Zheng Xu, Joshua Scheck, Markus D Boos, Deepti Gupta, Heather A Brandling-Bennet, Robert Sidbury, Ramesh S Iyer, Yongdong Zhao
BACKGROUND: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone disease requiring immunosuppressive treatment in half of patients. Monoclonal tumor necrosis factor inhibitors (TNFi) are often used as effective second-line off-label therapies. However, paradoxical psoriasis can occur in a subset of patients exposed to monoclonal TNFi and can prompt conversion to alternate therapy if severe. OBJECTIVE: The aim of this study was to determine the efficacy and safety of golimumab, a fully humanized TNFi, in children with CRMO, including those who develop paradoxical psoriasis after exposure to other monoclonal TNFi...
July 21, 2023: Paediatric Drugs